Log In
BCIQ
Print this Print this
 

AZD3293, LY3314814

  Manage Alerts
Collapse Summary General Information
Company AstraZeneca plc
DescriptionBeta-site APP-cleaving enzyme (BACE) inhibitor
Molecular Target Beta-site APP-cleaving enzyme 1 (BACE1) ; Beta-site APP-cleaving enzyme 2 (BACE2)
Mechanism of ActionBeta-site APP-cleaving enzyme 1 (BACE1) inhibitor; Beta-site APP-cleaving enzyme 2 (BACE2) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II/III
Standard IndicationAlzheimer's disease (AD)
Indication DetailsTreat Alzheimer's disease (AD); Treat early Alzheimer's disease (AD)
Regulatory Designation U.S. - Fast Track (Treat Alzheimer's disease (AD))
PartnerEli Lilly and Co.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$500.0M

0

$500.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

09/16/2014

$500.0M

0

$500.0M

Get a free BioCentury trial today